<DOC>
	<DOCNO>NCT00727298</DOCNO>
	<brief_summary>This study perform evaluate document safety efficacy infliximab ( RemicadeÂ® ) treatment chronic inflammatory disease big cohort daily routine practice rheumatologist , gastroenterologist , dermatologist .</brief_summary>
	<brief_title>Post Marketing Surveillance Study Remicade Patients With Chronic Inflammatory Diseases ( P04840 )</brief_title>
	<detailed_description>The study population choose non-probability sample . The safety population consist participant least one document infusion infliximab . The evaluable population consist participant &gt; =18 year age record indication infliximab use , available baseline data , least 3 infusion infliximab within first 16 week study . Baseline characteristic provide population .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Participants treat infliximab rheumatologist , gastroenterologist , dermatologists chronic inflammatory disease , rheumatoid arthritis , ankylose spondylitis , psoriatic arthritis , psoriasis , Crohn 's disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>